AstraZeneca-CICC Venture Capital Partnership, a venture capital fimr, led a $40m Series C round in Cullgen, a biotechnology company, with participation from Sincere Capital, Voyagers Capital, Wuxi Capital Group. “This new round of financing will enable Cullgen to accelerate development of its promising pipeline of targeted protein degraders featuring novel E3 ligands to potentially introduce new treatment approaches for patients battling cancer. We are extremely pleased with AstraZeneca’s support, and grateful to all our pre-eminent financial partners for their conviction in Cullgen’s position as world-class targeted protein degradation company," Ying Luo, Cullgen Chairman and CEO.